Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

NCT03393845 is registered in ClinicalTrials.gov with Nancy Chan, MD as lead sponsor.

NCT NCT03393845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03393845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Lead sponsor
Nancy Chan, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 29, 2018
Completion date
September 1, 2027
Enrollment
47 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer